{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:30:29Z","timestamp":1789389029094,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Greenville Hospital System"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00262-016-1809-6","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T11:43:38Z","timestamp":1455882218000},"page":"383-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A phase I\/IIa clinical trial in stage IV melanoma of an autologous tumor\u2013dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2"],"prefix":"10.1007","volume":"65","author":[{"given":"Julia M.","family":"Greene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Schneble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen O.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Vreeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth S.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark O.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Peoples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,19]]},"reference":[{"issue":"1","key":"1809_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11\u201330","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1809_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355(1):51\u201365","journal-title":"N Engl J Med"},{"issue":"10","key":"1809_CR3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351(10):998\u20131012","journal-title":"N Engl J Med"},{"key":"1809_CR4","first-page":"CD005413","volume":"1","author":"AD Sasse","year":"2007","unstructured":"Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA (2007) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 1:CD005413","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"1809_CR5","first-page":"S11","volume":"6","author":"MB Atkins","year":"2000","unstructured":"Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1):S11\u2013S14","journal-title":"Cancer J Sci Am"},{"issue":"27","key":"1809_CR6","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1200\/JCO.2005.03.202","volume":"23","author":"U Keilholz","year":"2005","unstructured":"Keilholz U, Punt CJ, Gore M et al (2005) Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European organisation for research and treatment of cancer melanoma group. J Clin Oncol 23(27):6747\u20136755","journal-title":"J Clin Oncol"},{"issue":"3","key":"1809_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.hoc.2014.02.002","volume":"28","author":"J Naidoo","year":"2014","unstructured":"Naidoo J, Page DB, Wolchok JD (2014) Immune checkpoint blockade. Hematol Oncol Clin North Am 28(3):585\u2013600","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"1809_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nrc3153","volume":"11","author":"P Sharma","year":"2011","unstructured":"Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11(11):805\u2013812","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1809_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"9948","key":"1809_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparsion cohort of a phase 1 trial. Lancet 384(9948):1109\u20131117","journal-title":"Lancet"},{"issue":"4","key":"1809_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"issue":"26","key":"1809_CR12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"issue":"2","key":"1809_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122\u2013133","journal-title":"N Engl J Med"},{"issue":"19","key":"1809_CR14","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19(19):5300\u20135309","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1809_CR15","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott D, Haanen J, Chen TT, Lorigan P, O\u2019Day S, Investigators MDX (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2\u00a0years following treatment in a phase III trial (MDX010-20). Ann Oncol 24(10):2694\u20132698","journal-title":"Ann Oncol"},{"issue":"2","key":"1809_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134\u2013144","journal-title":"N Engl J Med"},{"issue":"5","key":"1809_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422","journal-title":"N Engl J Med"},{"issue":"7","key":"1809_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28(7):1099\u20131105","journal-title":"J Clin Oncol"},{"issue":"11","key":"1809_CR19","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4161\/hv.29110","volume":"10","author":"EJ Schneble","year":"2014","unstructured":"Schneble EJ, Yu X, Wagner T, Peoples GE (2014) Novel dendritic cell-based vaccination in late stage melanoma. Human Vaccines Immunother 10(11):3132\u20133138","journal-title":"Human Vaccines Immunother"},{"issue":"2","key":"1809_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00002371-200103000-00006","volume":"24","author":"LM Holmes","year":"2001","unstructured":"Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y (2001) A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas. J Immunother 24(2):122\u2013129","journal-title":"J Immunother"},{"key":"1809_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nm0597-558","volume":"3","author":"J Gong","year":"1997","unstructured":"Gong J, Chen D, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic carcinoma cells. Nat Med 3:558\u2013561","journal-title":"Nat Med"},{"key":"1809_CR22","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.4049\/jimmunol.161.10.5516","volume":"161","author":"J Wang","year":"1998","unstructured":"Wang J, Saffold S, Cao X et al (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516\u20135524","journal-title":"J Immunol"},{"key":"1809_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/(SICI)1097-0215(19980413)76:2<250::AID-IJC13>3.0.CO;2-G","volume":"76","author":"L Lespagnard","year":"1998","unstructured":"Lespagnard L, Mettens P, Verheyden A et al (1998) Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 76:250\u2013258","journal-title":"Int J Cancer"},{"key":"1809_CR24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1046\/j.1365-2567.1999.00823.x","volume":"97","author":"X Cao","year":"1999","unstructured":"Cao X, Zhang W, Wang J et al (1999) Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97:616\u2013625","journal-title":"Immunology"},{"issue":"3","key":"1809_CR25","first-page":"585","volume":"28","author":"Y Wei","year":"2006","unstructured":"Wei Y, Sticca RP, Holmes LM et al (2006) Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28(3):585\u2013593","journal-title":"Int J Oncol"},{"issue":"3","key":"1809_CR26","first-page":"665","volume":"18","author":"YC Wei","year":"2007","unstructured":"Wei YC, Sticca RP, Li J et al (2007) Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol Rep 18(3):665\u2013671","journal-title":"Oncol Rep"},{"issue":"4","key":"1809_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther 37(4):764\u2013782","journal-title":"Clin Ther"},{"key":"1809_CR28","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Novolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"issue":"2","key":"1809_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21903","volume":"104","author":"N Wasif","year":"2011","unstructured":"Wasif N, Bagaria S, Ray P, Morton D (2011) Does metastectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 104(2):111\u2013115","journal-title":"J Surg Oncol"},{"key":"1809_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.seminoncol.2012.02.011","volume":"39","author":"HL Kaufman","year":"2012","unstructured":"Kaufman HL (2012) Vaccines for melanoma and renal cell carcinoma. Semin Oncol 39:263\u2013275","journal-title":"Semin Oncol"},{"key":"1809_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1586\/erv.11.74","volume":"10","author":"O Klein","year":"2011","unstructured":"Klein O, Schmidt C, Knights A et al (2011) Melanoma vaccines: developments over the past 10 years. Expert Rev Vaccines 10:853\u2013873","journal-title":"Expert Rev Vaccines"},{"key":"1809_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00002371-199807000-00001","volume":"21","author":"Y Kawakami","year":"1998","unstructured":"Kawakami Y, Robbins PF, Wang RF et al (1998) The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 21:237\u2013246","journal-title":"J Immunother"},{"key":"1809_CR33","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1200\/JCO.2003.10.005","volume":"21","author":"CL Slingluff Jr","year":"2003","unstructured":"Slingluff CL Jr, Petroni GR, Yamshchikov GV et al (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016\u20134026","journal-title":"J Clin Oncol"},{"key":"1809_CR34","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","volume":"15","author":"CL Slingluff Jr","year":"2009","unstructured":"Slingluff CL Jr, Petroni GR, Olson WC et al (2009) Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multi-peptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036\u20137044","journal-title":"Clin Cancer Res"},{"key":"1809_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/CMR.0b013e32834640c0","volume":"21","author":"MS Block","year":"2011","unstructured":"Block MS, Suman VJ, Nevala WK et al (2011) Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res 21:438\u2013445","journal-title":"Melanoma Res"},{"key":"1809_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/ijc.21264","volume":"117","author":"WH Kruit","year":"2005","unstructured":"Kruit WH, van Ojik HH, Brichard VG et al (2005) Phase I\/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117:596\u2013604","journal-title":"Int J Cancer"},{"key":"1809_CR37","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","volume":"31","author":"WH Kruit","year":"2013","unstructured":"Kruit WH, Suciu S, Dreno B et al (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma. J Clin Oncol 31:2413\u20132421","journal-title":"J Clin Oncol"},{"key":"1809_CR38","doi-asserted-by":"crossref","unstructured":"Sabado RL, Pavlick AC, Gnjatic S, et al (2012) Phase I\/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. ASCO Annual Meeting Abstracts. J Clin Oncol 30:Abstract 2589","DOI":"10.1200\/jco.2012.30.15_suppl.2589"},{"key":"1809_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11864-014-0283-7","volume":"15","author":"SA Weiss","year":"2014","unstructured":"Weiss SA, Chandra S, Pavlick AC (2014) Update on vaccine for high-risk melanoma. Curr Treat Options Oncol 15:269\u2013280","journal-title":"Curr Treat Options Oncol"},{"key":"1809_CR40","doi-asserted-by":"crossref","unstructured":"Kirkwood JM, Dreno B, Hauschild A, et al. (2011) DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. ASCO Annual Meeting Abstracts. J Clin Oncol 29:Suppl Abstract TPS232","DOI":"10.1200\/jco.2011.29.15_suppl.tps232"},{"key":"1809_CR41","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1200\/JCO.2012.47.9303","volume":"31","author":"AMM Eggermont","year":"2013","unstructured":"Eggermont AMM, Suciu S, Rutkowski P et al (2013) Adjuvant ganglioside GM2-KLH\/QS-21 vaccination vs observation after resection of primary tumor 1.5\u00a0mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831\u20133840","journal-title":"J Clin Oncol"},{"key":"1809_CR42","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00000658-200210000-00006","volume":"236","author":"DL Morton","year":"2002","unstructured":"Morton DL, Hseuh EC, Essner R et al (2002) Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236:438\u2013449","journal-title":"Ann Surg"},{"key":"1809_CR43","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1200\/JCO.2002.01.151","volume":"20","author":"EC Hsueh","year":"2002","unstructured":"Hsueh EC, Essner R, Foshag LJ et al (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549\u20134554","journal-title":"J Clin Oncol"},{"key":"1809_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10434-001-0198-y","volume":"8","author":"GJ Tsioulias","year":"2001","unstructured":"Tsioulias GJ, Gupta RK, Tisman G et al (2001) Serum TA90 Antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol 8:198\u2013203","journal-title":"Ann Surg Oncol"},{"key":"1809_CR45","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1517\/13543784.2012.684753","volume":"21","author":"A Mackiewic","year":"2012","unstructured":"Mackiewic A, Mackiewicz J, Wysocki PJ et al (2012) Longterm survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs 21:773\u2013783","journal-title":"Expert Opin Investig Drugs"},{"key":"1809_CR46","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1007\/s12032-012-0168-1","volume":"29","author":"S Markowicz","year":"2012","unstructured":"Markowicz S, Nowecki ZI, Rutkowski P et al (2012) Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol 29:2966\u20132977","journal-title":"Med Oncol"},{"key":"1809_CR47","doi-asserted-by":"crossref","unstructured":"Petenko NN, Mikhaylova IN, Chkadua GZ et al (2012) Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients. ASCO Annual Meeting Abstracts. J Clin Oncol. 30:Abstract 2524","DOI":"10.1200\/jco.2012.30.15_suppl.2524"},{"key":"1809_CR48","doi-asserted-by":"crossref","unstructured":"Andtbacka RHI, Collichio F, Amatruda T, et al. (2013) OPTIM: a randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous granulocyte macrophage colony-stimulating factor for the treatment of unresectable stage IIIB\/C and IV melanoma. ASCO Annual Meeting Abstracts. J Clin Oncol 31:Abstract LBA9008","DOI":"10.1200\/jco.2013.31.15_suppl.lba9008"},{"key":"1809_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"A Eggermont","year":"2015","unstructured":"Eggermont A, Chairion-Sileni V, Grob JJ et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind phase 3 trial. Lancet Oncol 16:522\u2013530","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"1809_CR50","doi-asserted-by":"publisher","first-page":"P208","DOI":"10.1186\/2051-1426-3-S2-P208","volume":"3","author":"D Jackson","year":"2015","unstructured":"Jackson D, Greene J, Hale D et al (2015) Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients. J ImmunoTherapy Cancer 3(Suppl 2):P208","journal-title":"J ImmunoTherapy Cancer"},{"key":"1809_CR51","doi-asserted-by":"crossref","unstructured":"Greene JM, Hale DF, Schneble EJ, et al. (2015) Initial phase I\/IIa trial results of an autologous tumor lysate\u00a0+\u00a0yeast cell wall particles\u00a0+\u00a0dendritic cells vaccine (TLPLDC) in patients with solid tumors. In: CRI-CIMT-EATI-AACR: the inaugural international cancer immunotherapy conference: translating science into survival. New York. AACR:Abstract A044","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A044"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-016-1809-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1809-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:41:25Z","timestamp":1744173685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-016-1809-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,19]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1809-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,19]]},"assertion":[{"value":"13 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Thomas Wagner is the Chief Executive Officer and Dr. George Peoples is the Chief Medical Officer of Orbis Health Solutions. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}